July 6, 2021: Press Release - Use of a Novel Adhesive Suture Retention Device in Lower Leg Excisional Wound Closure
June 12, 2021: Press Release - SUTUREGARD® Medical, Inc’s HEMIGARD™ Adhesive Retention Suture Device Used to Prevent Surgical Wound Dehiscence
September 8, 2020: Press Release - Patient Self-Removal of HEMIGARD During COVID Now Published
July 28, 2020: Press Release - SUTUREGARD® Medical and Federated Healthcare Supply Sign Non-Exclusive Distribution Deal
July 14, 2020: Press Release - SUTUREGARD® Medical Announces How To Document Use of their Devices in Modernizing Medicine’s EHR system, EMA®
March 2020: Press Release - SUTUREGARD® Medical, INC. is Presenting at the American Society of Plastic Surgery Annual Meeting
Feburary 2020: Press Release - Newly published research in the Journal of Clinical Biomechanics supports using novel devices, such as the SUTUREGARD® ISR Retention Suture Device and the HEMIGARD™ Adhesive Retention Suture Device, to initiate approximation of high-tension surgical wounds.
January 2020: Press Release - SUTUREGARD® Presenting at the American Society for Mohs Surgery
January 2020: Press Release - SUTUREGARD® Medical, Inc is Presenting at Arab Health
December 2019: SUTUREGARD® Operation Smile
November, 2019: Press Release - SUTUREGARD® Medical, Inc is Presenting at Arab Health
June, 2019: USPTO has issued US Patent No. 10, 327, 762 entitled, "Suture locks" to SUTUREGARD® Medical, Inc.
May, 2019: A clinical milestone for SUTUREGARD® Medical, Inc.: The SUTUREGARD® ISR device has been used in over 500 cases since first going to market November 2018!
April, 2018: SUTUREGARD® Medical, Inc. closes round of private equity funding.
December 2018: SUTUREGARD® Medical, Inc. awarded $95,600 Oregon Inc grant in Oregon's first enhanced phase 0 program.
November 8, 2018 - SUTUREGARD® Medical, Inc. launches sales at the ASMS Fundamentals of Mohs Surgery Conference. Thank you, customers!
October 25th, 2018: SUTUREGARD® wins Founders Live PDX pitch competition!
September 13, 2018: The US Patent Office has issued U.S. Patent No. 10,064,616 entitled “VARIABLE STIFFNESS SUTURE BRIDGES COMPATIBLE WITH VARIOUS SUTURE PATTERNS” to SUTUREGARD® Medical, Inc..
March 30, 2018: Dan Ladizinsky, MD assumes CEO position at SUTUREGARD® Medical, Inc..
March 27, 2018: Effective immediately, JULIVA™ Technologies Inc will go by the name “SUTUREGARD® Medical, Inc.” operating under JULVIA™ Technologies Inc. The move to a new name was a branding decision. SUTUREGARD® is a more intuitive reference to our product line-up.
March 20, 2018: SUTUREGARD® Medical, Inc. publishes pre-clinical study demonstrating effectiveness of SUTUEGARD® device in Advances in Wound Care
December 7, 2017: JULVIA™ Technologies Inc wins Pitch Oregon, seed stage competition.
November 15, 2017: OSU Venture Development Fund invests in JULVIA™ Technologies Inc.
Jen Akeroyd, PhD, RN, CEO/CoFounder of JULVIA™ Technologies Inc was named 2017 Entrepreneur of the Year by the Regional Accelerator and Innovation Network program.
JULVIA Technologies Inc research published in Journal of the Dermatology Nurses' Association showing the common prevalence of ingrowth of nonabsorbable sutures in dermatology.
JULVIA™ Technologies Inc research published in Journal of the Mechanical Behavior of Biomedical Materials showing deep sutures less effective than widely believed.
JULVIA™ Technologies Inc Wins Business Oregon Grant
JULVIA™ Technologies Inc Wins Synapse MedTech Pitch Competition